This site use cookies This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more ACCEPT Company Investors Technology Careers Updates Events Contact Transforming the lives of those suffering from vision loss Our mission is to profoundly improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss. ABOUT EXONATE A revolutionary eye drop entering Phase I clinical trials By exploiting the alternative splicing of vascular endothelial growth factor (VEGF) we aim to use our cutting-edge technology to introduce an eye drop to treat wet AMD and DMO. Our technology has the potential to become the patients’ treatment of choice. LEARN MORE Our experienced team is developing a revolutionary eye drop treatment supported by highly-respected investors At Exonate, we want to profoundly improve the lives of those suffering from vision loss. We believe that we have the potential to deliver eye drops to treat diseases such as wet AMD and DMO which will not only offer improved quality of life for patients, but also at a much lower administrative cost. Latest news & events Exonate is funded by international leading investors Who we are Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis) This is a key driver of disease progression in some ophthalmic conditions and cancers. Follow us on Social Media Useful links Career opportunities Technology Investors Contact Copyright © 2021 Exonate Privacy policy Designed and built by Onespacemedia